Elypta
Stockholm
About Elypta
Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $33.6M
- Funding stage: Early Stage Venture
- Last round: Grant (Mar 2023)
- Website: elypta.com
- Phone: +46 0 852 027 885
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/elypta-58256 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.